Software will eat AI! HSBC argues AI can’t threaten enterprise software

At a time when tech stocks are falling globally amid heightened uncertainties surrounding the impact of artificial intelligence (AI) on software companies, global financial firm HSBC believes AI will not kill the software industry, but the latter will be the primary mechanism for the diffusion of AI across the world’s largest enterprises.

HSBC, in its report on February 24, emphasised that “software is how the world’s largest companies controllably leverage AI.”

Tech stocks have witnessed a massive selloff lately, especially after the launch of Anthropic’s Claude, seen as a major disruptor across several industries, including IT. On Tuesday, February 24, the Nifty IT index crashed by almost 5%, bringing its February losses to 21%so far.

Tuesday’s selloff in the Indian IT counters followed a rout in Wall Street tech stocks after Anthropic said its Claude Code tool can help modernise Cobol- the programming language central to IBM’s operations for over 60 years.

Software is already eating AI, says HSBC

Emphasising that AI cannot threaten enterprise software, and rather, AI will be twitter-tweetded within software platforms. HSBC said AI is destined to be subordinate to the overall software platform.

“AI encompasses the creative analysis and production of intelligent data, and that data is passed to the software stack to be processed, stored, checked, formatted, presented, or actionised in a deterministic fashion. Thus, in large enterprise application platforms, we see subordinated AI as simply a part of an overall solution, and it is likely to be subjugated across applications by twitter-tweetding intelligent agents within the numerous enterprise platforms,” said HSBC.

HSBC believes these intelligent agents will likely be relegated to domain-specific high-value tasks that are difficult to codify and are better handled by a thinking entity.

“We believe that the far majority of enterprise software will not be threatened by AI, but rather AI will be domesticated within the application stack via agents and will create tremendous value in doing so,” said HSBC.

According to the global financial firm, software vendors are best suited to creating software with AI, not startups that use AI but lack the many success attributes and IP needed to compete.

“Large LLM model vendors are intensely focused on foundation model innovations and also lack the many success factors needed to win against or displace incumbents. And companies using AI to write their own applications are not practical, realistic, or economically sound,” HSBC said.

“Software vendors themselves are the best suited to use AI to generate software, as they have domain expertise, robust sales channels, trusted relationships, cross licensing, and legions of coders that are now more productive at creating new code by using new AI apps/tools,” HSBC said.

HSBC noted that while AI has been highly profitable for hardware and semiconductor companies, most of the value is now being generated in the software sector.

Software firms have been preparing for this shift by developing agentic AI over the past two years, with a major rollout expected in 2026.

HSBC says building or expanding select positions within the software vertical prior to a re-rating may be timely, as the sector valuations are at historical lows.

HSBC believes the software sector is poised to expand massively, with strong demand momentum expected to persist for the foreseeable future.

Disclaimer: This story is based on an HSBC report available on social media platforms. It is for educational purposes only. The views and recommendations expressed are those of individual analysts or broking firms, not Mint. We advise investors to consult with certified experts before making any investment decisions, as market conditions can change rapidly and circumstances may vary.

Latest

HCLTech, TCS, Infosys: Why are IT stocks falling again?

Fresh pressure on IT shares as demand concerns and foreign selling unsettle investors

Dr Reddy’s jumps nearly 7% as Sensex falls: Why is the pharma stock rising?

Shares of Dr Reddy’s Laboratories surged sharply on Thursday, bucking a weak broader market and emerging as one of the top gainers on the Nifty 50.

Sensex tumbles 650 points: Why is the stock market falling?

Stock markets remained sharply lower in early trade on Thursday as crude oil above $100, global uncertainty and broad-based selling in financial and IT stocks w

Sensex, Nifty sink as crude oil prices reach $100; IndiGo down 2%

The S&P BSE Sensex was down by 625.09 points to 77,891.40, while the NSE Nifty50 lost 173.90 points to 24,204.20 as of 9:26 am. 

Groww shares hit 52-week high: What’s driving the rally and should you buy now?

Groww shares soar to new heights, but brokerages offer mixed advice

Topics

Explained: Why stock markets are rising even as crude oil remains above $100

Benchmark indices rallied in early trade on Monday despite crude oil remaining elevated above $100. The move reflected bargain buying and global AI-led optimism

Sun Pharma’s biggest-ever bet: Why markets cheered the Organon mega deal

Sun Pharma just made the biggest bet in Indian pharma history. Markets loved it instantly. Here’s why investors backed the Organon deal despite the massive pr

Watch out Apple and Samsung, OpenAI is making AI smartphone with agentic capabilities

OpenAI is reportedly working with MediaTek and Qualcomm on smartphone processors, aiming to build an AI-first device powered by agent-led experiences.

ICSE, ISC board results to be out this week? Here’s what CISCE official has to say

The Council for the Indian School Certificate Examinations (CISCE) will declare the much-awaited ICSE Class 10 and ISC Class 12 Results 2026 shortly. Officials

Sam Altman says Codex is causing major FOMO so he changing his sleep schedule

Sam Altman says GPT-5.5 in Codex is so good he’s cutting sleep. He has said due to AI he has switched to polyphasic sleep — a schedule involving multiple sh

Cohance Lifesciences hits 20% upper circuit: Why the stock rising today?

Cohance Lifesciences jumped 20% after appointing former Cipla CEO Umang Vohra. Investors are betting his leadership can accelerate growth and transform the comp

30 students suspended at Hansraj College over fest chaos, DUSU calls it undemocratic

Hansraj College has placed around 30 students, including four elected union office-bearers, under interim suspension over alleged misconduct tied to its annual

Decoding the Sun Pharma $11.75 billion deal: Why the pharma stock jumped 7% today?

The stock was trading around Rs 1,739.70 as of 9:46 am, up over 7%, after touching a high of Rs 1,741.85 during the session, reflecting strong investor interest
spot_img

Related Articles

Popular Categories

spot_imgspot_img